The Centre has achieved over €8.2M in non-exchequer non-commercial (NE:NC) awards primarily from the EU research programme known as Horizon 2020 (H2020). 12 awards were granted for applications made to calls under the Excellent Science pillar totalling €6.2M and 10 of these awards were within the MSCA programme, one was a European Research Council grant and the other was a Future and Emerging Technologies grant.
International Leading Centre of Excellence
The SSPC aims to be an internationally leading Centre of excellence in synthesis and solid state pharmaceuticals. Acquiring funding and fostering collaboration with other leading international academics and centres is critical to achieving this aim. The objective of the SSPC's collaboration strategy is to enhance the scientific, engineering and technical capital available to the Centre.
The Centre initiated a national working group called (bio)Pharma Ireland to highlight the importance of innovation in pharmaceutical manufacturing in Europe. The (bio)Pharma Ireland working group, chaired by SSPC, has representation from pharmaceutical industry: BioPharma Chemical Ireland (BPCI), government agencies: Science Foundation Ireland, Enterprise Ireland and the IDA; and academic research organisations: National Institute for Bioprocessing Research and Training (NIBRT) and the Pharmaceutical Manufacturing and Technology Centre (PMTC).
The aim of (bio)Pharma Ireland is to increase opportunities for research collaborations for the pharma sector; and ultimately contribute to the development of European roadmaps and policy. Through (bio)Pharma Ireland, SSPC has embarked on a period of engagement and networking in order to influence and inform policy initiatives in support of advanced manufacturing. A number of bilateral meetings were held in Brussels with representatives from relevant European Technology Platforms (SPIRE, Factories of the Future, EuropaBio), DG Research and DG Innovation in June and October 2016. The purpose of these meetings was to identify and establish opportunities for the Centre to engage more in the current work programmes. In February 2017, (bio)Pharma Ireland hosted a pan-European seminar in Brussels on the Future of (bio)Pharmaceutical Manufacturing, with participation from the European Commission, European Parliament, Council Secretariat EU experts, academia, industry leaders (eg. Eli Lilly, Janssen, Helsinn, Agilent) and EU research centres. Over 80 delegates attended this event and voiced their support for the transformation of (bio)Pharma Ireland to a (bio)Pharma Europe initiative.
Formal International Collaborators
The SSPC team already has an extensive international collaboration portfolio. The SSPC builds on and enhances the level of strategic international collaboration to deliver the research programme, enhances knowledge exchange and supports funding diversification beyond the island of Ireland. The SSPC has already put in place international leading experts as official collaborators for SSPC2.
The SSPC has twelve formal international collaborators: Queens University Belfast, University of Rouen, University of Manchester, Delft University of Technology, University of Toronto, Radboud University Nijmegen, University of Leeds, CoEBio3/University of Manchester, CNRS, University of Marseille, University of Florida, Hong Kong Polytechnic University, C-SOPs/Purdue University.
The nature of funding bids has changed significantly in recent years and a significant part of the submission now involves project management experience. The SSPC has a dedicated funding project manager to support the researchers both in the preparation of bids and post-award project management is very beneficial particularly for large bids involving multiple partners.
Donal Killackey, National/EU Grants Manager, 061-234134.